Antibody
Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.
Timberlyne Therapeutics
PR-01-25-NI-07Jan 10, 2025
Agreement
Mediar Therapeutics and Lilly Sign Global Licensing Agreement to Advance WISP1 Antibody to Treat Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
PR-01-25-NI-06Jan 10, 2025
Antibody
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics, Inc.
PR-12-24-NI-125Dec 03, 2024
Financing
EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
EQT
PR-11-24-NI-116Nov 20, 2024
ADC
Chime Biologics and Waterstone Jointly Develop and Manufacture Antibody-Drug Conjugate (ADC)
Chime Biologics
PR-10-24-NI-91Nov 12, 2024
Announcement
Celebrating More than a Decade of Excellence at the World ADC Awards – Winners Announcement
World ADC
PR-10-24-NI-77Nov 08, 2024